You know things are bad when virtually all of the luminaries and thought leaders in a profession agree on certain negative indicators and a most likely scenario that will be the result of a confluence of “perfect storm” issues. That’s how it is with radiology these days. Lots of influential people in this space agree that change is here to stay, that it is mostly going to hurt, and that it is long overdue.

New data regarding the prevalence of Alzheimer's disease is looming far and above previous estimates: 17 percent higher than previously thought, according to statistics from Alzheimer's Disease International.

CHICAGO--The quest for a clear way forward in neurodegenerative imaging and therapeutics continues, with many of the same challenges continuing from previous years, according to a neuroimaging symposium during the Radiological Society of North America’s (RSNA) 99th annual meeting.

A number of exhibitors in attendance at last week’s Radiological Society of North America (RSNA) annual meeting in Chicago presented milestones in dose-technology development and hospital integration.

All major manufacturers of molecular imaging technologies now have PET/MR systems in their product portfolios. While Siemens is the only company to have an FDA approved, simultaneous PET/MR system on the market, a number of reports indicate that GE Healthcare is not too far behind in the research and development phase of an on-board and fully integrated PET/MR scanner, as evidence would have it at the 2013 Radiological Society of North America (RSNA) annual meeting still underway in Chicago until its conclusion tomorrow.

CHICAGO—Philips presented the new Vereos PET/CT system with solid state detectors at the 99th Radiological Society of North America (RSNA) annual meeting held Dec. 1-6 at McCormick Place convention center.

CMS elected to keep the new separate cost centers for MR and CT in its final rule, but did drop the most flawed group of cost data from the calculations thereby reducing cuts to the 2 to 18 percent range depending on modality and procedure

The rubidium-ARMI (alternative radiopharmaceutical for myocardial imaging) multicenter trial has established a bar for assessing myocardial perfusion imaging (MPI) that meets or even exceeds previous SPECT MPI reader scores after thorough consensus review, according to a study published Nov. 18 in the Journal of Nuclear Medicine.